DelveInsight’s “Liquid Biopsy – Market Insights, Competitive Landscape, and Market Forecast-2032” report delivers an in-depth understanding of the market dynamics, competitive landscape, key growth drivers, emerging technologies, and future opportunities shaping the global liquid biopsy industry.

Interested to know which liquid biopsy technologies will capture the highest market share?

Download the report to understand the latest liquid biopsy market trends and forecasts- https://www.delveinsight.com/report-store/liquid-biopsy-in-cancer-diagnostics-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from the Liquid Biopsy Market Report

• The global Liquid Biopsy market was valued at USD 7.64 billion in 2024 and is projected to reach USD 19.24 billion by 2032, growing at a CAGR of 16.64% during the forecast period.

• Rising incidence of cancers, including lung, breast, colorectal, and prostate cancers, is significantly increasing demand for non-invasive diagnostic solutions.

• Growing adoption of precision medicine and personalized oncology is accelerating the use of liquid biopsy technologies for treatment selection and monitoring.

• Technological advancements in Next-Generation Sequencing (NGS), digital PCR, multi-omics platforms, and AI-powered analytics are enhancing test accuracy and clinical utility.

• Multi-Cancer Early Detection (MCED) tests based on DNA methylation, circulating tumor DNA (ctDNA), and proteomics are emerging as major growth opportunities.

• North America represents the largest regional market, while Asia-Pacific is expected to witness the fastest growth during the forecast period.

• Increasing regulatory approvals, reimbursement support, strategic collaborations, and investments are strengthening market expansion globally.

• The germany liquid biopsy market, uk liquid biopsy market, italy liquid biopsy market, spain liquid biopsy market, gcc liquid biopsy market, and south america liquid biopsy market are expected to create significant future growth opportunities.

• Leading liquid biopsy companies include Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Guardant Health, Illumina Inc, Roche, QIAGEN, and others.

Gain a competitive edge in the Liquid Biopsy Market by exploring our in-depth analysis @ Liquid Biopsy Market Report – https://www.delveinsight.com/report-store/liquid-biopsy-in-cancer-diagnostics-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Liquid Biopsy Market Overview

The global liquid biopsy market is transforming cancer detection and monitoring through minimally invasive diagnostic techniques. Unlike conventional tissue biopsies, liquid biopsy analyzes circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and other biomarkers from blood and other bodily fluids, enabling real-time disease assessment and personalized treatment planning.

Growing cancer prevalence worldwide, combined with increasing demand for less invasive diagnostic procedures, continues to fuel market growth. The integration of advanced genomic technologies and AI-enabled bioinformatics solutions has further expanded the clinical applications of liquid biopsy across cancer diagnosis, treatment monitoring, relapse detection, and precision oncology. Furthermore, the expanding in vitro diagnostic liquid biopsy testing market is contributing significantly to the adoption of advanced molecular diagnostic approaches worldwide.

Factors Driving the Growth of the Liquid Biopsy MarketRising Global Cancer Burden

The increasing prevalence of cancer worldwide remains one of the primary growth drivers for the liquid biopsy market. Rising incidences of lung, breast, colorectal, prostate, and other cancers have created substantial demand for efficient diagnostic solutions that support early detection and continuous disease monitoring. Growing demand within the breast cancer liquid biopsy market is further accelerating product development and clinical adoption.

Shift Toward Minimally Invasive Diagnostics

Liquid biopsy offers a non-invasive alternative to conventional tissue biopsies, reducing procedural risks, patient discomfort, and healthcare costs. The ability to perform repeated sampling also supports ongoing treatment monitoring and assessment of tumor evolution.

Advancements in Genomic Technologies

Rapid advancements in NGS, digital PCR, and multi-omics technologies have significantly improved the sensitivity and specificity of liquid biopsy assays. These innovations have enhanced the detection of ctDNA, CTCs, exosomes, and other clinically relevant biomarkers.

Growing Use in Personalized / Precision Oncology

The increasing focus on precision medicine is driving demand for liquid biopsy technologies. These tests enable molecular profiling of tumors and help clinicians identify actionable mutations such as EGFR, ALK, KRAS, and BRAF, supporting personalized treatment decisions.

New Liquid Biopsy Companies Entering the Market

The growing commercial attractiveness of the sector continues to encourage new liquid biopsy companies to enter the market, supported by increasing investments, technological innovation, and expanding clinical applications.

Liquid Biopsy Market Segment Analysis

Among market segments, the services category accounted for approximately 73% of revenue share in 2024. The segment benefits from increasing demand for specialized services including sample collection, biomarker analysis, genomic sequencing, and data interpretation.

Several liquid biopsy companies provide comprehensive liquid biopsy service platforms supporting both clinical and research applications. The growing adoption of outsourced diagnostic services is expected to further strengthen segment growth during the forecast period.

Liquid Biopsy Market Regional AnalysisNorth America is Expected to Dominate the Overall Liquid Biopsy Market

North America is anticipated to maintain the largest market share owing to increasing cancer prevalence, strong oncology research infrastructure, favorable regulatory policies, and widespread adoption of innovative diagnostic technologies.

The United States accounted for approximately 87% of North America’s market revenue in 2024, supported by high healthcare spending, strong reimbursement frameworks, and increasing regulatory support for liquid biopsy technologies. Continued investments in cancer diagnostics and precision medicine are expected to sustain regional leadership.

Asia-Pacific is projected to be the fastest-growing region due to expanding healthcare infrastructure, rising cancer burden, increasing awareness, and growing adoption of advanced diagnostic technologies.

Meanwhile, the germany liquid biopsy market, uk liquid biopsy market, italy liquid biopsy market, and spain liquid biopsy market continue to gain momentum due to increasing utilization of precision medicine approaches. Emerging regions such as the gcc liquid biopsy market and south america liquid biopsy market are also witnessing growing adoption driven by healthcare modernization initiatives.

Liquid Biopsy Key Companies

Liquid Biopsy Companies include:

• Myriad Genetics Inc

• Exact Sciences Corporation

• Biocartis

• Sysmex Corporation

• Thermo Fisher Scientific Inc

• Biocept Inc

• Agilent Technologies Inc

• MDx Health

• NeoGenomics Laboratories

• F. Hoffmann-La Roche Ltd

• Guardant Health

• Bio-Techne

• Illumina Inc

• QIAGEN

• Lucence Health Inc

• Personal Genome Diagnostics Inc

• SAGA Diagnostics

• Agena Bioscience Inc

• The Menarini Group

• MiRXES Pte Ltd.

• And Others.

Download the report to understand which factors are driving Liquid Biopsy Market Trends

Latest Highlights from the Liquid Biopsy Market

• Guardant Health launched upgraded Guardant360 and GuardantINFINITY assays featuring enhanced tumor profiling capabilities.

• Roche expanded its AVENIO blood-based NGS oncology research test portfolio.

• FDA expanded approvals for liquid biopsy-based companion diagnostics, including additional indications for Guardant360 CDx.

• Natera’s Signatera MRD test received broader regulatory support across multiple cancer types.

• Increased adoption of AI-driven analytics and bioinformatics platforms continues to improve biomarker interpretation and variant detection.

• Strategic collaborations between diagnostics companies, pharmaceutical organizations, hospitals, and cancer centers are accelerating commercialization and adoption.

• Growth in the breast cancer liquid biopsy market and the broader in vitro diagnostic liquid biopsy testing market is expected to drive future innovation.

Discover key developments and opportunities in the Liquid Biopsy Market @ Liquid Biopsy Market Size

Liquid Biopsy Market Outlook

The liquid biopsy market is experiencing rapid growth as healthcare systems increasingly embrace minimally invasive cancer diagnostics. Advances in molecular profiling, genomic sequencing, AI-powered analytics, and multi-omics technologies are significantly improving the clinical utility of liquid biopsy tests.

The market is also benefiting from expanding applications in minimal residual disease (MRD) detection, treatment monitoring, recurrence prediction, and multi-cancer early detection (MCED). Growing investments, strategic partnerships, and regulatory support are expected to further accelerate innovation and commercialization.

As precision oncology continues to gain momentum, liquid biopsy technologies are positioned to become an integral component of cancer diagnosis and management, enabling earlier intervention, improved patient outcomes, and more personalized treatment strategies across the gcc liquid biopsy market, south america liquid biopsy market, and major European markets.

Scope of the Liquid Biopsy Market Report

Study Period: 2022–2032

Forecast Period: 2025–2032

Market Size (2032): USD 19.24 Billion

CAGR (2025–2032): 16.64%

Major liquid biopsy companies Companies: Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Genome Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., and others.

Market Segments Covered: Type, Sample Type, Biomarker Type, Cancer Type, Technique, End User, and Geography.

Competitive Intelligence Analysis: Market trends, competitive landscape, strategic collaborations, acquisitions, investments, regulatory approvals, and emerging technologies.

Key Focus Areas: Multi-Cancer Early Detection (MCED), Minimal Residual Disease (MRD), ctDNA Analysis, Precision Oncology, AI-Powered Diagnostics, and Next-Generation Sequencing Applications.

Table of Contents

1. Liquid Biopsy Market Report Introduction

2. Liquid Biopsy Market Executive Summary

3. Regulatory Analysis

4. Liquid Biopsy Market Key Factor Analysis

5. Liquid Biopsy Market Porter’s Five Forces Analysis

6. Liquid Biopsy Market Layout

7. Liquid Biopsy Market Company and Product Profiles

8. KOL Views

9. Project Approach

10. DelveInsight Capabilities

11. About DelveInsight

12. Disclaimer & Contact Us

How DelveInsight’s Liquid Biopsy Market Report Helps CXOs and Business Leaders

• Evaluate the current and future market opportunity across key regions, including the United States, Europe, Asia-Pacific, and Rest of the World, through detailed market forecasts, technology assessments, and growth trend analysis.

• Benchmark leading liquid biopsy technologies, products, and diagnostic platforms through comprehensive competitive intelligence, company profiling, product portfolio evaluation, and innovation tracking.

• Identify potential licensing, acquisition, co-development, and strategic partnership opportunities by monitoring emerging market participants, novel biomarker technologies, and recent industry collaborations, mergers, and investments.

• Assess the impact of upcoming regulatory approvals, technological advancements, reimbursement developments, and product launches on market share, pricing strategies, adoption rates, and commercial success.

• Support strategic decision-making with insights into key opinion leader (KOL) perspectives, unmet diagnostic needs, clinical adoption trends, biomarker utilization, patient stratification approaches, and evolving market dynamics within the Liquid Biopsy landscape.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/liquid-biopsy-in-cancer-diagnostics-market